SLP

Simulations Plus Inc

Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries.

Simulations Plus Inc (SLP) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (C-). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.6 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 46.3
EV / EBITDA 21.6
Rev Growth YoY 7.5%
Gross Margin 63.4%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $374.2M
TTM Revenue $82.1M
Price / Sales 4.6
ROE 6.2%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.6) C- (2.1) B (3.2) C+ (2.5) C+ (2.6) C+ (2.6)
2026-11-07 C (2.5) C- (2.1) B (3.2) C+ (2.5) C+ (2.7) C+ (2.6)
2026-10-31 C+ (2.6) C- (2.1) B (3.2) C+ (2.5) C+ (2.7) C+ (2.6)
2026-10-24 C+ (2.6) C- (2.0) B (3.2) C+ (2.5) C+ (2.6) C+ (2.6)
2026-10-17 C+ (2.6) C- (2.0) B (3.2) C+ (2.5) C+ (2.6) C+ (2.6)
Page 1 of 3